Global Psychedelic Drugs Market is expected to grow with the CAGR of 13.3% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-market
Global psychedelic drugs market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in global psychedelic drugs market are introducing strong range of products provider along with pipelines products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.
For instance;
Jazz Pharmaceuticals, Inc. is the market leader in psychedelic drugs market. The other player in this market are Pfizer Inc., Verrian, F. Hoffman-La Roche Ltd, Hikma Pharmaceuticals PLC, usonainstitute.org, GH Research, COMPASS, NRx Pharmaceuticals, INC, Celon Pharma SA, PharmaTher, Cybin Corp. among others.
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. headquartered in Dublin, Ireland was incorporated in 2003. The company is engaged in turning biopharmaceutical discoveries into novel changing drugs to treat rare or complex diseases. The company is providing products under the categories Medicine (our medicines, drug safety, and medical information), research (pipeline, clinical trials, extended access, and independent scientific research). The company is constantly engaged in the manufacture and development of psychedelic drugs.
The company has wide presence across North America, Europe through its subsidiaries Jazz Pharmaceuticals Ireland Limited (Ireland), Jazz Financing Eye Designed Activity Company (Ireland), Jazz Capital Limited (Ireland), Jazz Pharmaceuticals, Inc. (US), Celator Pharmaceuticals, Inc. (US) among others
Pfizer Inc.
Pfizer Inc. headquartered in New York, U.S. was founded in 1849. The company is engaged in research and development, manufacturing and sales of a wide range of products in the health care sector. The company is providing products such as Accupril, Accuretic, Altace, Amidate, Aromasin, Atgam, Azulfidine, Ketamine Hydrochloride, Pristiq (Desvenlafaxine) among many others in which the market focused product is Ketamine Hydrochloride, Pristiq (Desvenlafaxine). The company is constantly engaged in the manufacture and development of psychedelic drugs.
The company has various subsidiaries that are in Europe, Middle East and Africa, Americas, Asia-Pacific. The company has several owned subsidiaries involving Pfizer Animal Health B.V.( Netherlands), Pfizer Asia International B.V.(Netherlands), Pfizer Australia Superannuation Pty Ltd ( Australia), Pfizer Dominicana, S.A.(Dominican Republic), Pfizer Egypt S.A.E.(Egypt) among others
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd headquartered in Basel, Switzerland was founded in 1896. The company is one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. The company is providing products under the categories of Roche Pharma and Roche Diagnostics.
The company is constantly engaged in the manufacture and development of psychedelic drugs.
The company has various subsidiaries that are in America, Europe, Africa, Asia, and Oceania through its subsidiaries Roche Algeria SPA, Roche Diabetes Care Argentina S.A., Roche Diagnostics Australia Pty Limited, Roche Austria GmbH, Roche Bangladesh Limited among others.
Global Psychedelic Drugs Market – Industry Trends and Forecast to 2029
U.S. Psychedelic Drugs Market – Industry Trends and Forecast to 2029
Europe Psychedelic Drugs Market – Industry Trends and Forecast to 2029
North America Psychedelic Drugs Market – Industry Trends and Forecast to 2029
Middle East and Africa Psychedelic Drugs Market – Industry Trends and Forecast to 2029
Asia-Pacific Psychedelic Drugs Market – Industry Trends and Forecast to 2029
Jazz Pharmaceuticals, Inc. and Johnson & Johnson Services, Inc. are dominating the U.S. Psychedelic Drugs Market in 2019
Jazz Pharmaceuticals, Inc., Inc. Janssen Pharmaceuticals, Inc. (a Subsidiary of Johnson & Johnson Services, Inc.), Pfizer Inc. is Expected to Dominate the Europe Psychedelic Drugs Market in 2022
Jazz Pharmaceuticals, Inc. and Johnson & Johnson Services, Inc. are Dominating the North America Psychedelic Drugs Market in 2019